2021 off to a great start with M&A boom, PE investments & regulatory stimulus
The New Year has been remarkable in itself. With the global COVID-19 vaccination ramping up, the countries and economies are looking for bright sunshine that was dampened last year. Apart from this buzz, the other segments in healthcare are also making their presence felt. Of these, the medtech companies are on fire. In this month’s round up we discuss the M&A activities in medtech, growing investor interest in generics market and FDA’s new policy for biosimilars.